Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

RECOMMENDED

Uro-Oncology

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Lancet Oncol.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J

doi: 10.1016/S1470-2045(19)30415-2.

Uro-Oncology

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

BJU Int.

Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L

doi: 10.1111/bju.14999.

Uro-Oncology

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

BJU Int.

Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker P, Roobol MJ

doi: 10.1111/bju.14944.

Uro-Oncology

Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml

Prostate Cancer Prostatic Dis.

Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A

doi: 10.1038/s41391-019-0194-6.

Uro-Oncology

Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study

Cancer.

Gore JL, du Plessis M, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW

doi: 10.1002/cncr.30665.

Uro-Oncology

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Prostate.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M

doi: 10.1002/pros.23919.

Uro-Oncology

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

BJU Int.

Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A

doi: 10.1111/bju.15135.

Uro-Oncology

⁶⁸Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

J Urol.

Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP

doi: 10.1097/JU.

Uro-Oncology

Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [⁶⁸Ga]Ga-PSMA ligand PET/CT(MRI)

Prostate Cancer Prostatic Dis.

Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, Shariat SF, Rasul S

doi: 10.1038/s41391-020-00294-0.

Related content

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml

Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study

Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI)

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

⁶⁸Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [⁶⁸Ga]Ga-PSMA ligand PET/CT(MRI)